Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 3

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Breast Neoplasms 76Carcinoma, Non-Small-Cell Lung 73Multiple Myeloma 58Prostatic Neoplasms 57Colorectal Neoplasms 45Leukemia, Myeloid, Acute 43Neoplasms 41Melanoma 35Lymphoma 35Lung Neoplasms 32Ovarian Neoplasms 31Lymphoma, Non-Hodgkin 30Squamous Cell Carcinoma of Head and Neck 29Sarcoma 28Neoplasm Metastasis 27Pancreatic Neoplasms 26Endometrial Neoplasms 25Carcinoma, Hepatocellular 25Hodgkin Disease 23Carcinoma, Renal Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Lymphoma, Large B-Cell, Diffuse 22Leukemia, Lymphocytic, Chronic, B-Cell 22Glioma 22Recurrence 21Urinary Bladder Neoplasms 20Myelodysplastic Syndromes 20Head and Neck Neoplasms 20Esophageal Neoplasms 17Stomach Neoplasms 16

Interventions

Specimen Handling 3Biopsy 3X-Rays 2trastuzumab biosimilar HLX02 1pertuzumab 1erdafitinib 1copanlisib 1Trastuzumab 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1CT-P6 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Malignant Solid Neoplasm × 30 days × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT06351371 2026-05-28

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

NCT06360588 2026-05-28

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
22 enrolled 9 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡